About
Cardiovascular Therapeutics
Areas of Focus
Categories
Virus TechnologySmall Molecule PharmaceuticalGene Therapy, RNA & Peptide TherapyBiotech
Team (30)
Alexander Marson, M.D., Ph.D.
Tenaya Therapeutics
team_member
Amy Burroughs, MBA
Tenaya Therapeutics
team_member
Barry J. Byrne, M.D., Ph.D.
Tenaya Therapeutics
team_member
Benoit G. Bruneau, Ph.D.
Tenaya Therapeutics
team_member
Bruce R. Conklin, M.D.
Tenaya Therapeutics
team_member
Catherine Stehman-Breen, M.D.
Tenaya Therapeutics
team_member
Clinical Trials (4)
View allTotal Trials
4
As Lead Sponsor
4
As Collaborator
0
Total Enrollment
445
By Phase
PHASE1: 1PHASE1/PHASE2: 1
By Status
RECRUITING: 4
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
Today
Hover over trial bars to see details
Recent Trials
NCT06228924Lead Sponsor
Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC
PHASE1Recruiting
15 participants
Started: Mar 26, 2024 · Completed: Oct 1, 2029
NCT05836259Lead Sponsor
Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM
PHASE1/PHASE2Recruiting
30 participants
Started: Aug 10, 2023 · Completed: Aug 31, 2032
NCT06311708Lead Sponsor
Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
N/ARecruiting
200 participants
Started: Jan 31, 2023 · Completed: Jul 11, 2030
NCT05112237Lead Sponsor
Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy
N/ARecruiting
200 participants
Started: Nov 1, 2021 · Completed: Jun 30, 2028
Locations (1)
Headquarters
South SF, CA, United States
Map
Loading map...